MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)

被引：1
|
作者：
Richardson, Paul G.
Hofmeister, Craig C.
Siegel, David
Lonial, Sagar
Laubach, Jacob P.
Efebera, Yvonne A.
Vesole, David H.
Nooka, Ajay K.
Rosenblatt, Jacalyn
Raje, Noopur
Zaki, Mohamed H.
Hua, Ye
Li, Yan
Shah, Sheetal
Wang, Jianming
Anderson, Kenneth C.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1969
引用
收藏
页数：2
相关论文
共 50 条
  • [21] a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Berenson, James
    Stampleman, Laura
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall S.
    Eshaghian, Shahrooz
    Nassir, Youram
    Regina, Swift A.
    James, Wang
    Benjamin, Eades
    Spektor, Tanya M.
    Vescio, Robert
    BLOOD, 2015, 126 (23)
  • [22] A PHASE 2 MULTICENTER STUDY OF POMALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN JAPANESE PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: THE MM-011 TRIAL
    Hagiwara, S.
    Okamoto, S.
    Matsue, K.
    Iida, S.
    Sunami, K.
    Komeno, T.
    Suzuki, K.
    Ando, K.
    Taniwaki, M.
    Tobinai, K.
    Chou, T.
    Kaneko, H.
    Iwasaki, H.
    Uemura, C.
    Tamakoshi, H.
    Zaki, M. H.
    Doerr, T.
    Kuroda, Y.
    Ichinohe, T.
    HAEMATOLOGICA, 2016, 101 : 790 - 790
  • [23] MM-011: A Phase 2 Study of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma in Japan
    Hagiwara, Shotaro
    Okamoto, Shinichiro
    Matsue, Kosei
    Iida, Shinsuke
    Sunami, Kazutaka
    Komeno, Takuya
    Suzuki, Kenshi
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Tobinai, Kensei
    Chou, Takaaki
    Kaneko, Hitomi
    Iwasaki, Hiromi
    Uemura, Chie
    Tamakoshi, Hiromi
    Zaki, Mohamed H.
    Doerr, Thomas
    Kuroda, Yoshiaki
    Ichinohe, Tatsuo
    BLOOD, 2015, 126 (23)
  • [24] Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis
    Jagannath, Sundar
    Hofmeister, Craig C.
    Baz, Rachid C.
    Siegel, David Samuel DiCapua
    Vij, Ravi
    Chen, Christine
    Lonial, Sagar
    Anderson, Kenneth Carl
    Chen, Min
    Zaki, Mohamed H.
    Richardson, Paul Gerard Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability Of Pomalidomide plus Low-Dose Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment
    Matous, Jeffrey
    Siegel, David S.
    Duong, Hien K.
    Kasserra, Claudia
    Chen, Min
    Doerr, Thomas
    Sternas, Lars
    Zaki, Mohamed H.
    Jacques, Christian
    Shah, Jatin J.
    BLOOD, 2013, 122 (21)
  • [26] Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies
    Richardson, Paul G.
    Perrot, Aurore
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey S. Y.
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Mace, Sandrine
    Malinge, Laure
    Dubin, Franck
    Morisse, Mony
    Anderson, Kenneth C.
    BLOOD, 2022, 140
  • [27] Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
    Bahlis, Nizar J.
    Sutherland, Heather
    White, Darrell
    Sebag, Michael
    Lentzsch, Suzanne
    Kotb, Rami
    Venner, Christopher P.
    Gasparetto, Cristina
    Del Col, Aldo
    Neri, Paola
    Reece, Donna
    Kauffman, Michael
    Shacham, Sharon
    Unger, T. J.
    Jeha, Jacqueline
    Saint-Martin, Jean-Richard
    Shah, Jatin
    Chen, Christine
    BLOOD, 2018, 132 (24) : 2546 - 2554
  • [28] Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis
    Richardson, Paul
    Perrot, Aurore
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Malinge, Laure
    Dubin, Franck
    Morisse, Mony
    Anderson, Kenneth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S32 - S32
  • [29] Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Impact of Renal Function on Patient Outcomes
    Siegel, David S.
    Richardson, Paul G.
    Baz, Rachid
    Chen, Min
    Zaki, Mohamed
    Anderson, Kenneth C.
    BLOOD, 2012, 120 (21)
  • [30] Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
    Richardson, Paul G.
    Siegel, David S.
    Vij, Ravi
    Hofmeister, Craig C.
    Baz, Rachid
    Jagannath, Sundar
    Chen, Christine
    Lonial, Sagar
    Jakubowiak, Andrzej
    Bahlis, Nizar
    Song, Kevin
    Belch, Andrew
    Raje, Noopur
    Shustik, Chaim
    Lentzsch, Suzanne
    Lacy, Martha
    Mikhael, Joseph
    Matous, Jeffrey
    Vesole, David
    Chen, Min
    Zaki, Mohamed H.
    Jacques, Christian
    Yu, Zhinuan
    Anderson, Kenneth C.
    BLOOD, 2014, 123 (12) : 1826 - 1832
12345